 The N-terminus of GIP is essential for receptor activation  The C-terminus of GIP has no apparent interaction with the GIP receptor  C-terminal modifications of GIP has a minimal effect on receptor activation but its absence improves the antagonistic action for the GIP receptor
in the adrenal glands in patients with meal-related Cushing's disease, where it has been suggested to mediate a food-induced burst in hormone release initiated by GIP released from the GI tract [7] .
The therapeutic potential of GLP-1 was recognized when it was demonstrated to be capable of stimulating insulin secretion in patients with type 2 diabetes [8] . Nowadays, GLP-1 forms the basis of several marketed treatments of type 2 diabetes (T2D) and obesity exploiting its preserved insulinotropic properties and the inhibition of glucagon secretion, gastric emptying and appetite and food intake [9] . Unlike GLP-1, the insulinotropic action of GIP is severely impaired in patients with T2D, and a defective GIPR activity has been suspected to be a contributing factor, as supported by animal studies where a hyperglycemia-mediated downregulation of GIPR expression was observed in diabetic rodents [10, 11] . However, a causal link between identified GIPR SNPs and the GIP insensitivity in patients with T2D or obesity [12] [13] [14] [15] [16] [17] [18] has not been found. Possibly, the function of the GIPR is not impaired in human diabetes, as also suggested from recent human studies, where GLP-1/GIP co-agonists were claimed to activate the GIPR (in addition to the GLP-1 receptor (GLP-1R)) in patients with T2D [7, 19, 20] .
Both full length GIP and the naturally occurring truncated GIP peptides GIP(1-30)NH2 and GIP NH2 have been administered to humans. Infusions of GIP(1-42) (for two to six hours) in healthy individuals potentiate glucose-stimulated insulin secretion, augment glucagon secretion during hypoglycaemia, decrease bone resorption, increase blood flow and deposition of triacylglycerol in adipose tissue, mediate intestinal vasodilation, decrease blood pressure and increase heart rate [21] [22] [23] [24] [25] [26] [27] (see also Holst et al, this issue). In contrast, GIP infusions in patients with T2D result in very low insulin secretion [28] [29] [30] . In a single study, GIP(1-30)NH2 has been confirmed as a potent GIPR agonist when measuring insulin, glucagon, and markers of bone metabolism during various plasma glucose levels [31] . The GIPR antagonist, GIP(3-30)NH2, has been used as a tool to elucidate GIP physiology, and in these studies endogenous GIP has now been confirmed as an important incretin hormone in healthy men, but also confirmed its lack of effect in patients with T2D [32] [33] [34] [35] (see also Gasbjerg et al, this issue) . In contrast to the many studies in humans, where GIP agonists (GIP(1-42) and GIP(1-30)NH2) and the antagonist (GIP(3-J o u r n a l P r e -p r o o f 30)NH2) have been used to describe the acute physiological and pathophysiological roles of the GIP system, no long-term studies have been performed in humans with GIPR ligands as monotherapy. Multiple animal studies have evaluated GIPR functions and ligands, however, the results are often confounded by the marked species differences [36] . Furthermore, the conflicting results between rodent and human GIP pharmacology is contributed not only by potential differences in endogenous GIPR signaling but also by the assumption of similar agonist efficacy among species when performing pharmacological studies. Moreover, in rodents the GIP physiology is complicated and unclear as illustrated by reports that both GIP overexpression and GIPR gene deletion in mice resulted in improved glycaemic control and in a protection against diet induced-obesity [37, 38] .
In this review, we focus on how N-and C-terminal truncations of GIP(1-42) affect receptor binding and downstream signalling in both agonistic and antagonistic manners with an emphasis on the molecular pharmacology of their action.
Binding and activation mechanisms of class B1 GPCRs
The GIPR belongs to the G protein-coupled receptor (GPCR) superfamily andmore specificallythe class B1 receptor family [39, 40] . This means that, in terms of structure, the receptor has a transmembrane domain (TMD) consisting of seven transmembrane α-helices (helix I-VII), a single intracellular α-helix (helix VIII) and a well-structured, large extra-cellular N-terminal domain (ECD).
This receptor family recognizes a series of remarkably homogenous ligands, i.e. peptides of > 27 amino acid residues and of mostly α-helical nature [41, 42] . The exact activation mechanism of class B1 GPCRs, including the GIPR, is largely unknown. Educated guesses are based on data from X-ray crystallography, cryogenic electron microscopy (cryo-EM) or extrapolation of knowledge from other classes of GPCRs. Based on crystal and cryo-EM structures of the single GLP-1R and the glucagon receptor (GCGR) ( Fig.1) , the active and inactive states have been compared and reinforced by mutation studies. These studies have revealed the particular residues of importance in ligand binding and/or receptor activation within this receptor family [43] [44] [45] [46] . This model suggests that the peptide ligand diffuses through the interstitial fluid shifting between having α-helical fragments or a disordered secondary structure. The ECD of the receptor recognizes and "catches" the middle or C-terminal part (residues 15 to 30) of the ligand [48] after which the N-terminal part of the peptide moves to and docks into the TMD. During this process or as a result of this process, the well-conserved PLLG (proline-lysine-lysine-glycine) motif of the receptor in the middle of helix VI gets destabilized and changes conformation. The bottom of helix VI (as also seen in Fig.1 ) moves 10 -20 Å outwards, making an angle of 40 -60˚ with helix VII and creates space in the intracellular part of the receptor for cytosolic protein complexes to bind [49] . However, evidence of the exact transformation from active to inactive (or vice versa) is still lacking.
The signaling of the GIPR occurs mainly through binding of Gαs proteins which invoke multiple signaling cascades including increased levels of the downstream second messenger cAMP ( Fig.3 ). 40 Additionally, the conformational changes of the receptor also enhance the phosphorylation of helix VIII by G protein-coupled receptor kinases (GRKs), which subsequently recruit β-arrestins to this part of the receptor. β-arrestins desensitize the receptor by blocking the binding of Gαs proteins and by initiation of receptor trafficking, i.e. internalization and recycling [50] [51] [52] [53] [54] . Moreover, the GIPR has also been reported to signal from intracellular vesicles, i.e. endosomes [55] . A naturally occurring variant of the GIPR, GIPR-[E354Q] has recently been shown to enhance the internalization rate through enhanced GIP residence time [56] ; in agreement with the previous demonstration of decreased receptor recycling to the cell surface after internalization [54] . 
GIP peptides -agonists and antagonists obtained by truncations of GIP
Various GIP agonists and antagonists have been characterized in vitro and in vivo in rodents and some even in humans and have contributed to the understanding of the physiological actions of GIP [57] (summarized in Fig.4 ). GIP(1-42) is a substrate for the enzyme DPP-4 and has a short half-life in plasma [58] . DPP-4 cleaves peptide bonds following proline or alanine residues when positioned as the second amino acid counted from the N-terminus [59] . Therefore, the main circulating GIP(1-42) variant is the N-terminally truncated DPP-4 metabolite GIP(3-42) [58, 60] ( Fig.4 and 5A) . GIP(1-42) is processed from the precursor protein proGIP by the prohormone convertase (PC) 1/3 [61] , but also contains a PC2 cleavage motif, i.e. Gly31;Lys32;Lys33, which after cleavage yields GIP(1-30)NH2 and GIP (34) (35) (36) (37) (38) (39) (40) (41) (42) . PC2 is expressed in pancreatic α-cells [62] and a subpopulation of enteroendocrine K cells [63] 
GIPR agonists
As mentioned above, humans have (at least) two active circulating GIP variants -GIP(1-42) and the C-terminally truncated version, GIP(1-30)NH2 [63, 64] (Fig.5A ). Since GIP(1-30)NH2 is only present at very low plasma concentrations (low picomolar range), its physiological role is expected to be minimal or even absent [65] . From a molecular pharmacologically point of view, the two peptides bind to human GIPR with similar affinities and furthermore activate the receptor with 
Functional consequences of N-terminal truncations of GIP(1-42)
The N-terminus of GIP is essential for receptor activation as previously displayed by NMR, in silico molecular modeling, in vitro and in vivo experiments [66] [67] [68] [69] [70] [71] [72] [73] . Specifically, the N-terminal Tyr1 of GIP has been described to interact with residues of three different transmembrane helixes of the GIPR, namely Gln224 (helix III), Arg300 (helix V), and Phe357 (helix VI) [70, 73] . In addition, Ala2 is believed to play an important role as it is thought to interact with residues of helix III and form a J o u r n a l P r e -p r o o f hydrogen bond with Thr5 of GIP which seems to be important for receptor activation [70] . This is confirmed by in vitro studies in which N-terminal truncation of either Tyr1 (GIP(2-42)) or both Tyr1 and Ala2 (GIP(3-42)) result in low efficacy or no activity [66] [67] [68] . In addition, GIP(3-42) does not induce any insulin secretion from rat islets or pig pancreas [68] . Further N-terminal truncations of GIP(1-42) result in partial agonism (GIP(4-42), GIP , GIP , GIP and GIP(8-42)) or full activity (GIP(9-42)) [67] . In contrast, N-terminal truncations of GIP(1-30)NH2 result in no intrinsic activity [66] except for GIP (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) NH2 which acted as a partial agonist [74] (Fig. 4) . Thus, N-terminal truncations of GIP(1-30)NH2 show less intrinsic activity compared to N-terminal truncations of GIP . Since the naturally occurring GLP-1(7-36)NH2 and GLP-2(1-33) also lose activity and become partial agonists, when truncated N-terminally to GLP-1(9-36)NH2 and GLP-2(3-33), respectively, an intact N-terminus seems necessary to gain full receptor activation within the class B1 GPCR family [75] [76] [77] [78] (Fig.6A and B, respectively) . As confirmed by the overall receptor structures and proposed activation mechanism, described in section 2, the GIP system resembles the GLP-1 and GLP-2 systems in this way. 
The C-terminus of GIP peptides and GIPR agonism
GIP distinguishes itself by being C-terminally extended (amino acid [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , when comparing it to its most related class B1 peptides (Fig.6D) . From NMR data, GIP(1-42) appears to have disordered N-and C-termini (residues Tyr1 -Thr5 and Trp36 -Gln42), a stable α-helical backbone (between residues Phe6 -Gln29) and a less well-defined helix (between residues Lys30 -Trp36) [41] . Detailed analysis of the chemical shifts suggests that within the stable helical part of the peptide, one can distinguish two helical segments, i.e. between residues Ser8 -Lys16 and Gln19 -Lys30 [69] . A crystal structure published in 2007, proposes that the binding interface of GIP to the ECD spans from Asp15 to Lys30 and that since residues Lys32 to Gln42 could not be resolved, it is expected that the C-terminus shows a high degree of disorder [48] . The disorder observed in the last 12 residues of GIP(1-42), along with the fact that it does not bind to the ECD, nor to residues close to the TMD, indicate that these residues are of little importance for GIPR binding and receptor activation. As previously mentioned, GIP(1-42) and GIP(1-30)NH2 bind with identical affinity to the GIPR confirming the (in vitro) redundancy of residues Gly31 -Gln42 [63, 66] . Until very recently, no in vivo differences have been described regarding the intrinsic activity between GIP(1-42) and GIP(1-30)NH2. However, a recent human study indicated that GIP(1-30)NH2 infusion increases the glucagon levels more than GIP(1-42) under fasting conditions [31] . It is also likely that the C-terminus affects the overall stability of the GIP molecule as exemplified by variants with both C-and N-terminal truncations of GIP , where the presence of the C-terminus improves the agonistic action of the N-terminally truncated GIP peptides, as compared to the same N-terminal truncations in the absence of the C terminus [67] . Furthermore, due to the difference in structure, it could be speculated that GIP and GIP(1-30)NH2 may have different pharmacokinetic profiles, such as tissue distribution and clearance, however, this still remains to be verified.
GIPR antagonists

J o u r n a l P r e -p r o o f
Many approaches have been applied to develop potent and efficacious GIPR antagonists to study GIP physiology such as GIP or GIPR antibodies and even a vaccination against GIP in animal studies has been described [80] [81] [82] [83] [84] . In addition, several peptide-based antagonistic variants have been identified involving N-and C-terminal modifications of GIP and GIP(1-30)NH2 (Fig. 4) [ 66, 67, 85, 86] .
The N-terminus of GIP peptides and GIPR antagonism
As previously described, class B1 GPCRs are believed to be activated in a two-step ligand bindingactivation mechanism where the binding of the peptide N-terminus to the transmembrane domain of the receptor results in receptor activation [47] [48] [49] (Fig.2) . It is therefore to be expected that Nterminal truncations or modifications of the ligand will result in decreased efficacy. One of the first GIPR peptides to be described as an antagonist was (Pro3)GIP [85] . This peptide was used in a number of rodent studies to inhibit GIPR activity and this resulted in improved diabetic parameters and weight loss [85, [87] [88] [89] [90] . (Pro3)GIP was long believed to be an antagonist of the GIPR system, however, a thorough in vitro study revealed that human (Pro3)GIP is a full agonist of human GIPR and that the rodent variants are partial agonists of the rodent and human GIPRs [36] . Other amino acid substitutions at position 3 were found to be partial agonists of human GIPR [86] . This underlines the impact of the N-terminus in receptor activation, as also emphasized by the observation that the most potent GIPR peptide antagonists are N-terminal truncations of GIP(1-30)NH2 (Fig.4) . Truncation of the first two amino acids and up to 16 amino acids of GIP(1-30)NH2 leads to GIPR antagonists [66, 74, [91] [92] [93] [94] , among which GIP(3-30)NH2 and GIP(5-30)NH2 are most potent. Since GIP(3-30)NH2 is found naturally within the human circulation (being the DPP-4 product of GIP(1-30)NH2) this peptide has already been used in several clinical studies [24, 32-35, 95, 96] . It has, however, to be taken into account that GIP(3-30)NH2 shows species-dependent variation [97] , once again emphasizing that the GIP system is much less conserved between species than for example the GLP-1 system [98] .
The C-terminus of GIP peptides and GIPR antagonism
In comparison to GIPR agonism, C-terminally truncated GIP peptides have improved antagonistic properties. This is clearly exemplified by the two naturally occurring GIPR antagonists, GIP and GIP(3-30)NH2. In vitro, both peptides antagonize the human GIPR, however, GIP(3-30)NH2 is 26-fold more potent in doing so than GIP [66] . In addition, porcine GIP(3-42) was not able to inhibit GIP(1-42) mediated insulin secretion in pigs at physiological concentrations [68] , whereas human GIP(3-30)NH2 was able to reduce exogenous GIP-induced insulin secretion by at least 82% in humans [95] . This emphasizes that the C-terminus of GIP plays a role in GIPR antagonism as its absence improves the antagonistic action of the N-terminally truncated GIP peptides [66] .
The lack of impact for the C-terminus tail is also corroborated by GIP variants in which the Cterminus of exendin were inserted in exchange for the GIP C-terminus with lipidations to improve protein binding and thereby half-life extension [99] .
Conclusion
Based on the current literature it is clear that endogenous GIP peptides are suitable tools in the study of human GIP physiology/pathophysiology. Furthermore, due to the lack of success in designing small molecules targeting class B1 receptors, as opposed to the huge number of small molecule drugs developed for class A GPCRs, peptide-based GIPR ligands could be future therapeutics. The N-terminus of the GIP peptide is essential for receptor activation and N-terminal truncation leads to decreased or even lost intrinsic activity (similar to GLP-1 and GLP-2). The Cterminal extension of GIP, as compared to GLP-1, GLP-2 and glucagon, has no apparent interaction with the GIPR and may be important for properties such as stability, tissue accessibility and tissue specific signaling. Modifications of the C-terminus minimally affect receptor activation, while its absence improves the antagonistic action for GIPR. As such, nature has created a tool box of peptide agonists and antagonists that can be exploited from a pharmaceutical point of view, as was the case for the discovery of the successful agonists based on GLP-1 [100, 101] . In J o u r n a l P r e -p r o o f addition, a large number of chimeric dual or even triple acting compounds have already been designed on the basis of the native peptides and their receptor interactions [19, 20, [102] [103] [104] [105] .
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